Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 278

1.

Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.

Mercier S, Gueye NF, Cournil A, Fontbonne A, Copin N, Ndiaye I, Dupuy AM, Cames C, Sow PS, Ndoye I, Delaporte E, Simondon KB.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):224-30. doi: 10.1097/QAI.0b013e31819c16f4.

PMID:
19339897
2.
3.
4.

Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.

Fantoni M, Del Borgo C, Autore C, Barbaro G.

Ital Heart J. 2002 May;3(5):294-9. Review.

PMID:
12066561
5.

The metabolic toxicities of antiretroviral therapy.

Herman JS, Easterbrook PJ.

Int J STD AIDS. 2001 Sep;12(9):555-62; quiz 563-4. Review.

PMID:
11516363
6.

[Metabolic disturbances associated with HAART].

Olczak A.

Przegl Epidemiol. 2007;61(4):639-46. Review. Polish.

PMID:
18572495
7.

Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management.

Hirsch HH, Battegay M.

Infection. 2002 Oct;30(5):293-8. Review.

PMID:
12382089
8.

HIV and increased risk of cardiovascular diseases.

Das S.

Sex Health. 2005;2(4):219-21. Review.

PMID:
16402668
9.

Antiretroviral-therapy-associated lipoatrophy: current status and future directions.

Nolan D, Mallal S.

Sex Health. 2005;2(3):153-63. Review.

PMID:
16335543
10.
11.

[Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].

Streinu-Cercel A, Ion DA, Chivu LI, Chivu RD.

Rev Med Chir Soc Med Nat Iasi. 2006 Jul-Sep;110(3):521-5. Review. Romanian.

PMID:
17571539
12.

[Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients].

Leclercq P, Blanc M.

Rev Prat. 2006 May 15;56(9):987-94. Review. French.

PMID:
16775979
13.

Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.

Grinspoon SK.

Am J Med. 2005 Apr;118 Suppl 2:23S-28S. Review.

PMID:
15903292
14.
15.

[Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].

Calza L, Manfredi R, Chiodo F.

Recenti Prog Med. 2004 May;95(5):265-75. Review. Italian.

PMID:
15202680
16.

Metabolic syndrome associated with HIV and highly active antiretroviral therapy.

Barbaro G, Iacobellis G.

Curr Diab Rep. 2009 Feb;9(1):37-42. Review.

PMID:
19192423
17.

[Cardiovascular risk factors associated with antiretroviral therapy].

Pérez-Camacho I, Camacho A, Torre-Cisneros J, Rivero A.

Enferm Infecc Microbiol Clin. 2009 Sep;27 Suppl 1:24-32. doi: 10.1016/S0213-005X(09)73442-1. Review. Spanish.

PMID:
20172412
18.

Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.

Vigouroux C, Gharakhanian S, Salhi Y, Nguyên TH, Adda N, Rozenbaum W, Capeau J.

Diabetes Metab. 1999 Nov;25(5):383-92. Review.

19.

Disorders of body fat distribution in HIV-1-infected patients.

Moreno S, Miralles C, Negredo E, Domingo P, Estrada V, Gutiérrez F, Lozano F, Martínez E.

AIDS Rev. 2009 Jul-Sep;11(3):126-34. Review.

PMID:
19654854
20.

Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.

Leonard EG, McComsey GA.

Infect Dis Clin North Am. 2005 Sep;19(3):713-29. Review.

PMID:
16102657
Items per page

Supplemental Content

Support Center